Medigap Underwriting: Can it be Passed?

​Medigap insurance, also known as Medicare Supplement Insurance, is designed to fill the gaps in coverage left by Original Medicare. While Medigap plans offer standardized benefits, insurance companies may use underwriting processes to determine eligibility and pricing for beneficiaries. Understanding Medigap underwriting is crucial for individuals considering these plans and exploring their options for supplemental coverage.

What is Medigap Underwriting?

Medigap underwriting refers to the process used by insurance companies to assess an individual's health status and determine eligibility for a Medigap plan. Unlike Original Medicare, which is available to most individuals aged 65 and older regardless of health status, Medigap plans may involve medical underwriting.

During the underwriting process, insurance companies may review an applicant's medical history, pre-existing conditions, and other health related factors to evaluate their risk level. This assessment helps insurers determine the premiums they will charge for Medigap coverage.

Auto-Decline Medication List

One aspect of Medigap underwriting is the consideration of certain medications, which may lead to automatic declines in coverage. Understanding auto-decline medications for Medigap insurance underwriting is important for individuals seeking supplemental coverage and managing the intricacies of the application process.

Auto-Decline medications refer to specific prescription drugs or classes of medications that, if present in an applicant's medical history, may result in automatic denial of coverage insurance by insurance companies offering Medigap plans. These medications are typically associated with chronic or serious health conditions that may increase the insurers risk.

While the list of auto-decline medications may vary among insurance companies, certain classes of drugs are commonly associated with automatic declines in Medigap underwriting. Some examples include:

• Cancer Treatments:  Chemotherapy drugs, immunotherapy agents, and other medications used in the treatment of cancer are often considered high-risk by insurance companies and may lead to automatic declines in coverage.
• Immunomodulators: Medications that modulate the immune system, such as certain biologic agents used to treat autoimmune diseases like rheumatoid arthritis or Crohn's disease, may result in automatic denials due to their potential for serious side effects.
• Anti Rejection Medications:  Immunosuppressants prescribed to prevent organ rejection in transplant recipients, such as tacrolimus or cyclosporine, are typically considered high-risk and may lead to auto-decline decisions by insurers.
• HIV/AIDS Treatments: Antiretroviral drugs used in the treatment of HIV/AIDS are often associated with automatic declines in Medigap underwriting due to the chronic and serious nature of the condition.

​
Impact on Coverage

The presence of auto-decline medications in an applicant's medical history may lead to automatic denials of coverage for Medigap plans. Insurance companies assess the risk associate with these medications and may deem applicants ineligible for coverage based on their health status. 

Can Medigap Underwriting Be Passed?

Whether Medigap underwriting can be "passed" depends on the specific criteria set by insurance companies and state regulations. In some cases, individuals with certain health conditions may face higher premiums or be denied coverage altogether.

However, there are situations where Medigap underwriting may be bypassed or mitigated. Federal law provides certain protections for individuals who are guaranteed issue rights. These rights ensure access to Medigap coverage without medical underwriting, typically during  specific enrollment periods. Examples of guaranteed issue rights include enrolling in a Medigap plan within six months of enrolling in Medicare Part B or losing other health coverage.

Some states have regulations that restrict or prohibit medical underwriting for Medigap plans. In these states, insurance companies may be required to offer Medigap coverage to all Medicare beneficiaries, regardless of health status or pre-existing conditions.

Insurance companies must offer a six-month open enrollment period for Medigap plans, during which individuals have guaranteed issue rights and cannot be denied coverage based on health status. This period begins when a beneficiary is both 65 or older and enrolled in Medicare Part B.

In some cases, individuals with pre-existing conditions may still be eligible for Medigap coverage by may face a waiting period before certain benefits are covered. During this time, the insurance company may not pay for services related to the pre-existing condition.

Certain life events, such as moving to a new area or losing employer-sponsored coverage, may trigger a special enrollment period for Medigap plans. During these periods, individuals have guaranteed issue rights and can enroll in a plan without medial underwriting.

In conclusion, Medigap underwriting plays a significant role in determining eligibility and pricing for Medicare Supplement Insurance. While some individuals may face challenges due to health conditions, there are opportunities to access Medigap coverage through guaranteed issue rights, open enrollment periods, state regulations, and special enrollment periods. It's important for Medicare beneficiaries to understand their rights and options regarding Medigap underwriting, and to explore the available plans to find coverage that meets their healthcare needs and financial situation. Consulting with a licensed insurance agent or Medicare advisor can provide valuable guidance in navigating the complexities of Medigap underwriting and choosing the right supplemental coverage. Prairie Grove Insurance is here to assist you!

To Get Help Now, Call Our Office

​Rob Davies
Prairie Grove Insurance
800-254-5200
​608-839-0275